Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An announcement from PAVmed ( (PAVM) ) is now available.
On June 23, 2025, Veris Health Inc., a subsidiary of PAVmed Inc., completed a $2.5 million offering by selling shares and warrants to accredited investors, aimed at funding the development of its implantable physiological monitor and general operations. This strategic move enhances Veris’ financial position and provides investors with future participation rights, potentially strengthening its market presence and operational capabilities.
The most recent analyst rating on (PAVM) stock is a Buy with a $19.00 price target. To see the full list of analyst forecasts on PAVmed stock, see the PAVM Stock Forecast page.
Spark’s Take on PAVM Stock
According to Spark, TipRanks’ AI Analyst, PAVM is a Neutral.
PAVmed’s overall stock score reflects a combination of financial challenges and strategic positives. While the company is on a path of strategic expansion and has shown some financial improvements, significant operational and cash flow issues remain. The technical indicators suggest bearish momentum, and while the valuation appears favorable, the lack of dividends and high leverage are concerns. The earnings call highlighted strategic initiatives that slightly outweigh the risks, contributing positively to the score.
To see Spark’s full report on PAVM stock, click here.
More about PAVmed
PAVmed Inc. operates in the medical device industry, focusing on innovative products such as implantable physiological monitors through its majority-owned subsidiary, Veris Health Inc.
Average Trading Volume: 163,630
Technical Sentiment Signal: Sell
Current Market Cap: $10.03M
For a thorough assessment of PAVM stock, go to TipRanks’ Stock Analysis page.